Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 2a Study of VTX3232 in Parkinson's Disease
Sponsor: Zomagen Biosciences Ltd.
Summary
This is a study to understand if taking VTX3232 is safe in participants diagnosed with early stage idiopathic Parkinson's Disease (PD). Approximately 10 patients will take VTX3232 Dose A. The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 7-day Pre-Baseline Period, a 28-day Open Label Treatment period (a participant receives active Dose A), and a 14-day Follow-Up Period.
Official title: A Phase 2a, Single Site, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTX3232 in Participants With Early-Stage Parkinson's Disease
Key Details
Gender
All
Age Range
40 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
11
Start Date
2024-08-08
Completion Date
2025-04-04
Last Updated
2026-04-15
Healthy Volunteers
No
Conditions
Interventions
VTX3232
Dose A
Locations (1)
Local Site #840001
New Haven, Connecticut, United States